Skip to main content

CPRX

Stock
Health Care
Biotechnology

Performance overview

CPRX Price
Price Chart

Forward-looking statistics

Beta
Risk

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Company info

SectorHealth Care
IndustryBiotechnology
Employees119
Market cap$1.8B

Fundamentals

Enterprise value$2.1B
Revenue$534.6M
Revenue per employee
Profit margin36.91%
Debt to equity0.39

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$1.57
Dividend per share
Revenue per share$4.47
Avg trading volume (30 day)$28M
Avg trading volume (10 day)$30M
Put-call ratio

Macro factor sensitivity

Growth+0.9
Credit+4.4
Liquidity+1.6
Inflation-4.1
Commodities-1.5
Interest Rates-3.1

Valuation

Dividend yield0.00%
PEG Ratio14.21
Price to sales4.90
P/E Ratio14.21
Enterprise Value to Revenue3.87
Price to book3.29

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

CPRX or STVN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research (July 9, 2025)
Top 3 Health Care Stocks You'll Regret Missing This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga (June 26, 2025)
CPRX vs. NBIX: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research (June 23, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free